Q1 2026 Bio/Pharma Private Funding Remains Difficult, But Stage Is Set for a Rebound
- 4 days ago
- 4 min read
Updated: 15 hours ago
Q1 2026 private biotech funding remains low and did not match the January-driven peak seen in early 2025, but overall capital deployment remained broadly comparable. Unlike Q1 2025’s front-loaded start, funding in Q1 2026 was more evenly distributed across the quarter, pointing to a more stable, though still selective, investment environment. We still believe the stage is set for a rebound in private biotech funding starting in the 2nd half of 2026.
In total, private companies raised approximately $11.1B across 213 funding events in Q1 2026, compared to ~$12.0B across 301 events in Q1 2025 and ~$8.2B across 303 events in Q1 2024. While capital levels remained elevated versus 2024, a sharp decline in deal volume highlights continued investor selectivity. Early-stage funding also declined year-over-year, while grant activity increased to 44 events (~21% of total), underscoring the growing importance of non-dilutive capital.
Private Funding Activity
Private funding activity remained muted in Q1 2026, with 213 total events, down from ~300 deals in both Q1 2024 and Q1 2025 (Table 1 & Fig. 1).
January led the quarter with 100 deals, followed by a sharp drop in February (54) and March (59)
The decline in deal volume reflects continued selectivity in capital deployment
Grant activity remained elevated, accounting for ~21% of total events, higher than prior years
Overall, the data suggests that while investors are still active, fewer companies are securing funding, particularly outside of high-conviction opportunities.
Table 1. Q1 Private Bio/Pharma Funding Snapshot (2024–2026)
Q1 2024 | Q1 2025 | Q1 2026 | |
Total Funding | ~$8.16B | ~$11.96B | ~$11.08B |
Total Events | 303 | 301 | 213 |
Grants | 41 | 36 | 44 |
Early-Stage Funding | ~$2.86B | ~$3.38B | ~$2.27B |
Early-Stage Events | 119 | 117 | 73 |
Total Private Funding Amounts
Despite lower deal volume, capital deployment remained relatively stable (Fig. 2).
Q1 2026 funding totaled ~$11.1B, only slightly below Q1 2025 (~$12.0B) and well above Q1 2024 (~$8.2B)
Unlike 2025, where funding was heavily concentrated in January ($6.3B), 2026 showed a more balanced distribution. This shift suggests a less event-driven funding environment, with capital deployed more consistently across the quarter.
Early-Stage Funding
Early-stage funding remained under pressure in Q1 2026, both in terms of amounts and deal count (Fig. 3).
Early-stage funding totaled ~$2.27B across 73 deals, down from ~$3.38B across 117 deals in Q1 2025
January remained the strongest month (~$1.25B), followed by a sharp decline in February and partial recovery in March
While early-stage investment has not fully rebounded, continued deal flow indicates sustained investor interest, albeit with increased selectivity and smaller round sizes.
Public Market Sentiment
Public biotech markets showed mixed but stable performance in Q1 2026, following the strong recovery observed in the second half of 2025.
The XBI index opened the quarter at 121.52 on January 2 and closed at 127.73 on March 31, representing a ~5.1% increase. While the index experienced some volatility and softened during March, it remained well above mid-2025 levels (~77–83 range), when sentiment in small- and mid-cap biotech was significantly weaker.
The IBB index moved from 169.00 at the start of January to 168.85 at the end of March, reflecting a ~0.1% decline over the quarter. After a strong recovery through late 2025 (~120 in April 2025 to ~170 by year-end), the index showed signs of consolidation in Q1 2026, particularly in March.
Overall, public markets in Q1 2026 appear to be consolidating after the gains seen in late 2025, rather than entering a new upward phase. This stable but non-accelerating backdrop aligns with the continued selectivity observed in private funding activity, particularly at the early stage.
Concluding Remarks
Q1 2026 reflects a more balanced but still selective funding environment. While total capital raised remained broadly in line with prior years, deal volume and early-stage activity continued to decline. We still believe that the private biotech funding environment will improve significantly in the 2nd half of 2026. This is based on a continued elevated small-cap biotech public market, which has led to an opening of the public biotech market, as we predicted, which should then lead to an increase in private funding (Read our prior blog post)
Data Source: BiopharmIQ
About DHL
At DHL, we help private biotech teams build and execute IP strategies that hold up in diligence and support fundraising and partnering, whether you’re a Series A founder building your first portfolio or a late-stage C-suite/BD/IP leader managing a complex platform. We often operate less like traditional outside counsel and more like an embedded, contract in-house IP team, working closely with R&D, business development, and internal IP leads (agents or attorneys) to quickly understand the scientific nuances, stay aligned as priorities evolve, and translate strategy into an execution-ready filing roadmap and prosecution plan. We take a long-term approach: our rates are typically 33–50% lower than peer top-tier life sciences firms, we often invest significant upfront time to establish a strong foundation, and when timelines or budgets tighten between milestones, we offer flexible ways to keep the portfolio moving forward without sacrificing quality or strategic alignment. Learn more about DHL and meet the team.
Want to stay updated on life science patent law? Subscribe to get notified of updates
The content on this website (including all pages, articles, and comments) is not legal advice, and does not and is not intended to form or constitute any attorney-client relationship. The content is not a solicitation for business; it is for educational and entertainment purposes only, and reflects the personal views of the author(s) only and not those of any past, present, or future client of DHL. Any content should be double-checked for accuracy and current applicability, and liability is disclaimed for any error or omission.
4/20/26 Published (MD, RF, EJV)
Comments